These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 15037444

  • 21. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis.
    Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, Emery P, Marzo-Ortega H.
    Rheumatology (Oxford); 2008 Jun; 47(6):897-900. PubMed ID: 18403400
    [Abstract] [Full Text] [Related]

  • 22. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
    Davis JC, Van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO, Inman RD, de Vries T, Tsuji WH.
    J Rheumatol; 2005 Sep; 32(9):1751-4. PubMed ID: 16142873
    [Abstract] [Full Text] [Related]

  • 23. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
    van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé R, Assessment of SpondyloArthritis international Society (ASAS).
    Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
    [Abstract] [Full Text] [Related]

  • 24. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis JC.
    J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
    [Abstract] [Full Text] [Related]

  • 25. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept.
    Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.
    J Rheumatol; 2004 Mar; 31(3):531-8. PubMed ID: 14994401
    [Abstract] [Full Text] [Related]

  • 26. Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy.
    Jauregui E, Conner-Spady B, Russell AS, Maksymowych WP.
    J Rheumatol; 2004 Dec; 31(12):2422-8. PubMed ID: 15570645
    [Abstract] [Full Text] [Related]

  • 27. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [Abstract] [Full Text] [Related]

  • 28. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
    Tse SM, Burgos-Vargas R, Laxer RM.
    Arthritis Rheum; 2005 Jul; 52(7):2103-8. PubMed ID: 15986366
    [Abstract] [Full Text] [Related]

  • 29. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
    Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmartí R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S.
    Ann Rheum Dis; 2004 Dec; 63(12):1594-600. PubMed ID: 15345498
    [Abstract] [Full Text] [Related]

  • 30. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [Abstract] [Full Text] [Related]

  • 31. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis.
    Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J.
    Ann Rheum Dis; 2004 Nov; 63(11):1438-44. PubMed ID: 15044211
    [Abstract] [Full Text] [Related]

  • 32. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [Abstract] [Full Text] [Related]

  • 33. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.
    de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, van Denderen JC, Dijkmans BA, Wolbink GJ.
    Ann Rheum Dis; 2009 Apr; 68(4):531-5. PubMed ID: 18375542
    [Abstract] [Full Text] [Related]

  • 34. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
    Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, van der Heijde D, Braun J.
    Ann Rheum Dis; 2008 Apr; 67(4):511-7. PubMed ID: 17644552
    [Abstract] [Full Text] [Related]

  • 35. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.
    Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A, Skeith KJ, Aaron SL, Homik J, Davis P, Sholter D, Russell AS.
    Arthritis Rheum; 2002 Mar; 46(3):766-73. PubMed ID: 11920413
    [Abstract] [Full Text] [Related]

  • 36. Infliximab treatment in ankylosing spondylitis: an observational study.
    Nikas SN, Alamanos Y, Voulgari PV, Pliakou XI, Papadopoulos CG, Drosos AA.
    Ann Rheum Dis; 2005 Jun; 64(6):940-2. PubMed ID: 15564309
    [Abstract] [Full Text] [Related]

  • 37. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis.
    Choi ST, Kim JH, Kang EJ, Lee SW, Park MC, Park YB, Lee SK.
    Rheumatology (Oxford); 2008 Dec; 47(12):1775-9. PubMed ID: 18854347
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study.
    Marzo-Ortega H, McGonagle D, O'Connor P, Emery P.
    Arthritis Rheum; 2001 Sep; 44(9):2112-7. PubMed ID: 11592375
    [Abstract] [Full Text] [Related]

  • 39. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
    Rejón E, Giménez MD, Mayordomo L, Rodríguez S, González MP, Marenco JL.
    Scand J Rheumatol; 2004 Sep; 33(5):323-6. PubMed ID: 15513681
    [Abstract] [Full Text] [Related]

  • 40. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD, Sack KE, Davis JC.
    N Engl J Med; 2002 May 02; 346(18):1349-56. PubMed ID: 11986408
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.